PMV Pharmaceuticals (NASDAQ: PMVP) is a clinical-stage oncology biopharmaceutical company developing targeted therapies for patients with genomically-defined cancers. The company generates no product revenue, funding operations through capital raises, including an IPO completed September 24, 2020, and interest income from cash, cash equivalents, and marketable securities. Its lead program is rezatapopt, a small-molecule p53 reactivator targeting tumors with specific TP53 mutations. PMVP operates as a pre-commercial entity, with all expenses directed toward research and development and general and administrative functions. The company competes against pharmaceutical, biotechnology, and related companies pursuing targeted therapies in genomically-defined cancers. As of the 10-K filed March 6, 2026 (fiscal year ended December 31, 2025), PMVP remained pre-revenue and relied on its cash and marketable securities balance to fund ongoing clinical development activities.

Revenue model

No product revenue as of fiscal year ended December 31, 2025. The company funds operations through equity capital raises and earns interest income from cash, cash equivalents, and marketable securities holdings.

Products and services

Lead product candidate: rezatapopt, a targeted small-molecule therapy for patients with genomically-defined cancers involving p53 mutations. Additional future product candidates referenced but not named in the excerpts. All candidates are pre-commercial and subject to FDA approval processes including PMA or equivalent regulatory review.

Customers and end markets

End market is oncology, specifically patients with genomically-defined cancers harboring specific TP53 mutations. No commercial customers as of fiscal year ended December 31, 2025. Potential future customers would include hospitals, oncology clinics, and patients under physician direction.

Value-chain role

Drug discovery and clinical-stage development. PMVP conducts preclinical and clinical research, manufactures or contracts manufacturing for investigational compounds, and will require companion diagnostic partnerships for genomic patient selection. The company is pre-commercialization and has not yet reached regulatory approval or sales.

Geographic exposure

Primary operations in the United States. Clinical trials and regulatory activities reference FDA processes. EU GDPR obligations noted, indicating some European clinical trial activity or data processing exposure.

Competitors

Pharmaceutical and biotechnology companies pursuing targeted therapies in genomically-defined cancers (not individually named in filing excerpts)

Source: SEC 10-K, filed 2026-03-06

Industry: Pharmaceutical Preparations Peers: 2seventy bio, Inc. Stoke Therapeutics Inc G1 Therapeutics, Inc. Immunovant Inc Janux Therapeutics Inc Kezar Life Sciences Inc Kinnate Biopharma Inc. Vanda Pharmaceuticals Inc